<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93F82619-4BD0-4973-B51D-2600DB517FE8"><gtr:id>93F82619-4BD0-4973-B51D-2600DB517FE8</gtr:id><gtr:name>Tau Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0AE78E21-4E32-4EC6-AAC0-AC6DE757CCBC"><gtr:id>0AE78E21-4E32-4EC6-AAC0-AC6DE757CCBC</gtr:id><gtr:name>Nissan Chemical Industries Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93F82619-4BD0-4973-B51D-2600DB517FE8"><gtr:id>93F82619-4BD0-4973-B51D-2600DB517FE8</gtr:id><gtr:name>Tau Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0AE78E21-4E32-4EC6-AAC0-AC6DE757CCBC"><gtr:id>0AE78E21-4E32-4EC6-AAC0-AC6DE757CCBC</gtr:id><gtr:name>Nissan Chemical Industries Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7F0AF387-6463-4BEE-AD2B-F78BF5259487"><gtr:id>7F0AF387-6463-4BEE-AD2B-F78BF5259487</gtr:id><gtr:firstName>Andrea</gtr:firstName><gtr:surname>Cove-Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700536"><gtr:id>09767EA5-F2F4-4520-BB6A-F145DBCA4AE2</gtr:id><gtr:title>In Vivo Study of T-Type Calcium Channel Antagonism in Proliferative Renal Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0700536</gtr:grantReference><gtr:abstractText>In the UK there are currently over 40000 people suffering from kidney failure. This disease is fatal without some form of kidney replacement therapy such as dialysis or kidney transplantation. Dialysis treatment carries significant risks itself and can be very time consuming and inconvenient. Transplantation is unfortunately not readily available to all those who would benefit from it. Kidney damage is caused by many different conditions including diabetes, high blood pressure and diseases that cause inflammation in the kidney. However, uncontrolled growth of cells called mesangial cells in the filter units of the kidney is often the final pathway towards scarring and loss of function. As yet there are no specific treatments designed to prevent this uncontrolled cell division so it generally leads to progressive loss of functional kidney tissue and eventual kidney failure. Studies in the lab have shown that blocking a certain type of calcium channel on the surface of these cells can stop them from dividing so rapidly. This project is designed to see whether blocking this channel can prevent uncontrolled growth of these cells in a rat model of kidney disease. This will give us some indication of whether this strategy could be of use in reducing scarring and delaying the onset of end stage kidney failure in humans.</gtr:abstractText><gtr:technicalSummary>Background
Aberrant proliferation of mesangial cells is a key pathological step in many renal diseases. Current therapies for these conditions are limited and drugs targeting mesangial cell proliferation would be of considerable benefit.

Calcium plays a vital role in intracellular signalling. There is increasing evidence that T-type voltage gated calcium channels (T-CaCN) are involved in controlling proliferation in a number of cell types including vascular smooth muscle cells. Work in the Hendry lab has shown inhibition of T-CaCN using specific inhibitors (TTL-1177, mibefradil) and by the use of RNAi reduces human and rat mesangial cell proliferation in vitro. TTL-1177 has also been used by our collaborator Dr Lloyd Gray in an animal model of prostate cancer where it was shown to be anti-proliferative and was not associated with any obvious toxicity. 

Aims and Objectives
The aim is to delineate the potential role of T-type channels in proliferative renal disease and to investigate how these channels interact with the cell cycle machinery. If initial animal experiments using an acute nephritis model are successful, the model will be developed to create progressive renal damage so that effects of T-type calcium channel inhibition on the progression of fibrosis after glomerular injury may be studied. 

Methodology
The Thy1 model of nephritis in rats will be used. A single injection of Thy1 antibody leads to proliferation of mesangial cells and a transient glomerulopathy. Test groups will be treated with a daily injection of T-type calcium channel antagonist. Control animals will be given Thy1 nephritis and receive vehicle injections only. Sacrifice will occur at days 8 and 14, preceded by BrDU injection at -4 hrs. End points measured will include the immunohistochemical analysis of glomerular mesangial cell and monocyte numbers and study of glomerular cell proliferation by BrDU detection. Analysis of serum creatinine and urinary protein creatinine ratio will also be performed.

Parallel experiments will be performed in vitro using rat mesangial cells to examine the effects of pharmacological inhibition and RNAi knockdown of T-CaCN on the cell cycle. These experiments will define the phase of cell cycle inhibition and examine putatative links between T-CaCN and calmodulin kinase activity, phosphoMAP kinase level and cyclin expression.

This work will increase our understanding of the mechanisms of action of T-type calcium channels in cell proliferation and will indicate whether T-type calcium channel inhibition is of sufficient promise to justify further work towards clinical study in man.</gtr:technicalSummary><gtr:fund><gtr:end>2011-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>229535</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tau Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>TH1177 in renal disease</gtr:description><gtr:id>C09CAAD8-59DE-4E05-8407-B61F1A9383C7</gtr:id><gtr:impact>PMID: 19672121</gtr:impact><gtr:outcomeId>sEhFMYZuLr6-1</gtr:outcomeId><gtr:partnerContribution>Tau therapeutics have provided T-type calcium channel inhibitors for our in vitro and in vivo studies and have also contributed significant expertise in the field of calcium signalling to assist in this work.</gtr:partnerContribution><gtr:piContribution>I performed the in vitro and in vivo studies using TH1177 (alongside other calcium channel blocking agents) to target aberrant mesangial cell proliferation in renal disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nissan Chemical Industries Ltd</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Efonidipine and mesangial cell proliferation</gtr:description><gtr:id>912E4531-D7CA-45F0-9851-21493175BF3F</gtr:id><gtr:impact>Further knowledge about the potential benefits of efonidipine in renal disease.
The data contributed to the award of my PhD</gtr:impact><gtr:outcomeId>J66ifpLGdNP-1</gtr:outcomeId><gtr:partnerContribution>Nissan Chemical industries supplied racemic efonidipine and R-efonidipine for use in these experiments</gtr:partnerContribution><gtr:piContribution>I carried out in vitro and in vivo experiments assessing the efficacy of efonidipine and its individual enantiomers in reducing mesangial cell proliferation</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meeting with Tau therapeutics</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>FC6C43CA-D1C5-4AF0-9DEA-AC4007FF621C</gtr:id><gtr:impact>Data presented and discussed with private company which led to discussion afterwards.

Resulted in ongoing collaboration with Tau therapeutics</gtr:impact><gtr:outcomeId>LhS6bkCRVd1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with Abbott laboratories</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7A7AC9CD-BBFB-4AAC-83B8-3B37780B19B8</gtr:id><gtr:impact>Experts from pharmaceutical and business background at Abbott laboratories met to discuss future directions and priorities in renal therapeutics.

T-type calcium channel inhibition in renal disease became an area of interest for a large pharmaceutical company.</gtr:impact><gtr:outcomeId>sD6FadHki8P</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to local renal units</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>6C6B5C29-1240-4FCE-B046-130944508B3C</gtr:id><gtr:impact>20-50 health care professionals attended a presentation which enhanced their understanding of the research field and potential future therapeutic advances.

Increased awareness of the need for improved therapeutic strategies for preventing the progression of CKD and the role that selective calcium channel blockade may have in this.</gtr:impact><gtr:outcomeId>Ji6rUDbZ5C3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007,2009,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's College London Integrated Academic Training</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>099CA734-1C87-4D04-8A40-E7038D71AE93</gtr:id><gtr:outcomeId>BD3sGaRVUCp</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Academic Clinical Lecturer scheme</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B5AB081A-16DB-4C27-94F1-50570F42F06D</gtr:id><gtr:outcomeId>Gzc1U83oZNd0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The intervention is the use of TH1177 (or other T-type calcium channel blocking agent) to slow the progression of renal disease. The most recent stage of development has been the demonstration in both short-term and long-term animal models that TH1177 treatment leads to statistically significant improvements in key histological parameters of renal disease. This MRC clinical training fellowship was the principle source of funding for this development.</gtr:description><gtr:id>FC3A8826-D606-4953-BA6E-9AED2DE98A3C</gtr:id><gtr:impact>The proof of concept in animal models using this agent has contributed to interest in using it in humans for other disease processes and also to developing similar compounds with more specific properties for use in renal disease.</gtr:impact><gtr:outcomeId>W7W9Tv2fgDL</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>TH1177</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D96AF3BC-DCCA-4E1A-8084-57F606B09CC8</gtr:id><gtr:title>Anti-proliferative actions of T-type calcium channel inhibition in Thy1 nephritis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e440ce56220b3161515e52e9e9f6a633"><gtr:id>e440ce56220b3161515e52e9e9f6a633</gtr:id><gtr:otherNames>Cove-Smith A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>pm_14562_22_23746655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C54CCB73-7E5A-4665-9128-98D1C9AD2ABB</gtr:id><gtr:title>Inhibition of human mesangial cell proliferation by targeting T-type calcium channels.</gtr:title><gtr:parentPublicationTitle>Nephron. Experimental nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/634aacd773479540ecf148a1bc361b34"><gtr:id>634aacd773479540ecf148a1bc361b34</gtr:id><gtr:otherNames>Mulgrew CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1660-2129</gtr:issn><gtr:outcomeId>apYsivi4vTV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74536A4F-1D1B-464C-BA70-6E8B9BE38FF8</gtr:id><gtr:title>The regulation of mesangial cell proliferation.</gtr:title><gtr:parentPublicationTitle>Nephron. Experimental nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e440ce56220b3161515e52e9e9f6a633"><gtr:id>e440ce56220b3161515e52e9e9f6a633</gtr:id><gtr:otherNames>Cove-Smith A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1660-2129</gtr:issn><gtr:outcomeId>E563F1FB00B</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700536</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>